Monoclonal antibodies directed to the HER2 receptor
AssigneeGenentech, Inc.
InventorsRobert M. Hudziak, H. Michael Shepard, Axel Ullrich, Brian M. Fendly
Life of this patent
Estimating the term…
Abstract
Monoclonal antibodies which bind to the extracellular domain of the HER2 receptor and inhibit growth of SK-BR-3 breast tumor cells, which overexpress HER2, are disclosed. The monoclonal antibodies can be used for in vitro assays for detecting a tumor characterized by amplified expression of HER2.
Claims39
A monoclonal antibody which specifically binds to the extracellular domain of the HER2 receptor and inhibits growth of SK-BR-3 breast tumor cells in cell culture by greater than 20%, at an antibody concentration on of 0.5-30 .mu.g/ml, wherein said SK-BR-3 cells are cultured in culture medium comprising 10% fetal bovine serum and said growth inhibition is determined six days after exposure of said SK-BR-3 cells to said antibody.
A monoclonal antibody which specifically binds to the extracellular domain of the HER2 receptor, sensitizes tumor cells to TNF-.alpha., and inhibits growth of SK-BR-3 breast tumor cells in cell culture by greater than 20% at an antibody concentration on of 0.5-3.0 .mu.g/ml, wherein said growth inhibition is determined six days after exposure of said SK-BR-3 cells to said antibody.
A monoclonal antibody which specifically binds to the extracellular domain of the HER2 receptor, sensitizes tumor cells to cisplatin, and inhibits growth of SK-BR-3 breast tumor cells in cell culture by greater than 20%, at an antibody concentration of 0.5-3.0 .mu.g/ml, wherein said growth inhibition is determined six days after exposure of said SK-BR-3 cells to said antibody.
A monoclonal antibody which specifically binds to the extracellular domain of the HER2 receptor, sensitizes tumor cells to doxorubicin, and inhibits growth of SK-BR-3 breast tumor cells in cell culture by greater than 20% at an antibody concentration, of 0.5 -3.0 .mu.g/ml, wherein said growth inhibition is determined six days after exposure of said SK-BR-3 cells to said antibody.
A monoclonal antibody which binds to the HER2 receptor epitope to which monoclonal antibody 4D5 (ATCC CRL 10463) binds.
A monoclonal antibody which has the identifying biological characteristics of monoclonal antibody 4D5 (ATCC CRL 10463).
A monoclonal antibody which specifically binds to the extracellular domain of the HER2 receptor and sensitizes tumor cells to TNF-.alpha..
A monoclonal antibody which specifically binds to the extracellular domain of the HER2 receptor and sensitizes tumor cells to cisplatin or doxorubicin.
Dependencies are inferred from the claim text.